189 related articles for article (PubMed ID: 23364317)
1. Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.
van Loenen MM; de Boer R; Hagedoorn RS; Jankipersadsing V; Amir AL; Falkenburg JH; Heemskerk MH
Gene Ther; 2013 Aug; 20(8):861-7. PubMed ID: 23364317
[TBL] [Abstract][Full Text] [Related]
2. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells.
van Meerten T; Claessen MJ; Hagenbeek A; Ebeling SB
Gene Ther; 2006 May; 13(9):789-97. PubMed ID: 16421601
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
4. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
5. Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis.
Serafini M; Bonamino M; Golay J; Introna M
Haematologica; 2004 Jan; 89(1):86-95. PubMed ID: 14754610
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.
Circosta P; Granziero L; Follenzi A; Vigna E; Stella S; Vallario A; Elia AR; Gammaitoni L; Vitaggio K; Orso F; Geuna M; Sangiolo D; Todorovic M; Giachino C; Cignetti A
Hum Gene Ther; 2009 Dec; 20(12):1576-88. PubMed ID: 19678763
[TBL] [Abstract][Full Text] [Related]
7. Genetically modulating T-cell function to target cancer.
Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
[TBL] [Abstract][Full Text] [Related]
8. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
9. Suicide genes as safety switches in T lymphocytes.
Straathof KC; Spencer DM; Sutton RE; Rooney CM
Cytotherapy; 2003; 5(3):227-30. PubMed ID: 12850790
[TBL] [Abstract][Full Text] [Related]
10. Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation.
van Loenen MM; Hagedoorn RS; de Boer R; van Egmond EH; Falkenburg JH; Heemskerk MH
J Immunother; 2011 Mar; 34(2):165-74. PubMed ID: 21304404
[TBL] [Abstract][Full Text] [Related]
11. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
12. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
13. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.
Budde LE; Berger C; Lin Y; Wang J; Lin X; Frayo SE; Brouns SA; Spencer DM; Till BG; Jensen MC; Riddell SR; Press OW
PLoS One; 2013; 8(12):e82742. PubMed ID: 24358223
[TBL] [Abstract][Full Text] [Related]
14. Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.
Ochi T; Fujiwara H; Yasukawa M
Expert Opin Biol Ther; 2011 Jun; 11(6):699-713. PubMed ID: 21413911
[TBL] [Abstract][Full Text] [Related]
15. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
Schaft N; Lankiewicz B; Drexhage J; Berrevoets C; Moss DJ; Levitsky V; Bonneville M; Lee SP; McMichael AJ; Gratama JW; Bolhuis RL; Willemsen R; Debets R
Int Immunol; 2006 Apr; 18(4):591-601. PubMed ID: 16507598
[TBL] [Abstract][Full Text] [Related]
16. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy.
Griffioen M; van Egmond EH; Kester MG; Willemze R; Falkenburg JH; Heemskerk MH
Haematologica; 2009 Sep; 94(9):1316-20. PubMed ID: 19734426
[TBL] [Abstract][Full Text] [Related]
17. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
18. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
[TBL] [Abstract][Full Text] [Related]
19. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
Okamoto S; Mineno J; Ikeda H; Fujiwara H; Yasukawa M; Shiku H; Kato I
Cancer Res; 2009 Dec; 69(23):9003-11. PubMed ID: 19903853
[TBL] [Abstract][Full Text] [Related]
20. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI
J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]